Chryseobacterium/Elizabethkingia species infections in Saudi Arabia

References

1. ↵
   1. Vandamme P,
   2. Bernardet J-F,
   3. Segers P,
   4. Kersters K,
   5. Holmes B

   (1994) New perspectives in the classification of the flavobacteria:Description of Chryseobacterium gen. rev Int J Syst Bacteriol 44:827–831.

   OpenUrl
2. ↵
   1. Rishika Mehta Ashish Pathak Emerging Chryseobacterium indologenes infection in Indian neonatal intensive care units:A case report

   (2018) Antibiotics 7:pii:E109.

   OpenUrl
3. ↵
   1. Nulens E,
   2. Bussels B,
   3. Bols A,
   4. Gordts B,
   5. Van Landuyt H W

   (2001) Recurrent bacteremia by Chryseobacterium indologenes in an oncology patient with a totally implanted intravenous device. Clin Microbiol Infect 7:391–393.

   OpenUrlCrossRefPubMed
4. ↵
   1. Mirza HC,
   2. Tuncer Ö,
   3. Ölmez S,
   4. Şener B,
   5. Tuğcu GD,
   6. Özçelik U,
   7. et al.

   (2018) clinical Strains of Chryseobacterium and Elizabethkingia spp isolated from pediatric patients in a university hospital:Performance of MALDI-TOF MS-based identification, antimicrobial susceptibilities, and baseline patient characteristics. Microb Drug Resist 24:816–821.

   OpenUrl
5. ↵
   1. Chen FL,
   2. Wang GC,
   3. Teng SO,
   4. Ou TY,
   5. Yu FL,
   6. Lee WS

   (2013) Clinical and epidemiological features of Chryseobacterium indologenes infections:Analysis of 215 cases. J Microbiol Immunol Infect 46:425–432.

   OpenUrlCrossRefPubMed
6. ↵
   1. Kirby JT,
   2. Sader HS,
   3. Walsh TR,
   4. Jones RN

   (2004) Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp:report from the SENTRY Antimicrobial Surveillance Program (1997-2001). J Clin Microbiol 42:445–448.

   OpenUrlAbstract/FREE Full Text
7. ↵
   1. Asaad AM,
   2. Al-Ayed MS,
   3. Qureshi MA

   (2013) Emergence of unusual nonfermenting Gram-negative nosocomial pathogens in a Saudi hospital. Jpn J Infect Dis 66:507–511.

   OpenUrlCrossRefPubMed
8. ↵
   1. Esposito S,
   2. Russo E,
   3. De Simone G,
   4. Gioia R,
   5. Noviello S,
   6. Vitolo M,
   7. et al.

   (2015) Transient bacteraemia due to Chryseobacterium indologenes in an immunocompetent patient:a case report and literature review. J Chemother 27:324–329.

   OpenUrl
9. ↵
   1. Osamu Imataki Makiko Uemura Chryseobacterium indologenes a possible emergent organism resistant to carbapenem antimicrobials after stem cell transplantation

   (2017) Clin Case Rep 5:22–25.

   OpenUrl
10. ↵
    1. Lin JN,
    2. Lai CH,
    3. Yang CH,
    4. Huang YH

    (2019) Elizabethkingia Infections in Humans:From Genomics to Clinics. Microorganisms 7:pii:E295.

    OpenUrl
11. ↵
    1. Jean SS,
    2. Lee WS,
    3. Chen FL,
    4. Ou TY,
    5. Hsueh PR

    (2014) Elizabethkingia meningoseptica :an important emerging pathogen causing healthcare-associated infections. J Hosp Infect 86:244–249.

    OpenUrlCrossRefPubMed
12. 1. Aykac K,
    2. Ozsurekci Y,
    3. Tuncer O,
    4. Sancak B,
    5. Cengiz AB,
    6. Kara A,
    7. Ceyhan M

    (2016) Six cases during 2012-2015 and literature review of Chryseobacterium indologenes infections in pediatric patients. Can J Microbiol 62:812–819.

    OpenUrl
13. ↵
    1. Gunnarsson G,
    2. Baldursson H,
    3. Hilmarsdottir I

    (2002) Septic arthritis caused by Chryseobacterium meningosepticum in an immunocompetent male. Scand J Infect Dis 34:299–300.

    OpenUrlPubMed
14. ↵
    1. Han MS,
    2. Kim H,
    3. Lee Y,
    4. Kim M,
    5. Ku NS,
    6. Choi JY,
    7. et al.

    (2016) Relative prevalence and antimicrobial susceptibility of clinical isolates of Elizabethkingia species based on 16S rRNA gene sequencing. J Clin Microbiol 28(55):274–280.

    OpenUrl
15. ↵
    1. Rolston KV,
    2. Vaziri I,
    3. Frisbee-Hume S,
    4. Streeter H,
    5. LeBlanc B

    (2004) In vitro antimicrobial activity of gatifloxacin compared with other quinolones against clinical isolates from cancer patients. Chemotherapy 50:214–220.

    OpenUrlCrossRefPubMedWeb of Science